3P9G

Crystal structure of the TSG101 UEV domain in complex with FA459 peptide

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.80 Å
  • R-Value Free: 0.242 
  • R-Value Work: 0.197 
  • R-Value Observed: 0.197 

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history. 


Literature

Elucidation of New Binding Interactions with the Tumor Susceptibility Gene 101 (Tsg101) Protein Using Modified HIV-1 Gag-p6 Derived Peptide Ligands.

Kim, S.E., Liu, F., Im, Y.J., Stephen, A.G., Fivash, M.J., Waheed, A.A., Freed, E.O., Fisher, R.J., Hurley, J.H., Burke, T.R.

(2011) ACS Med Chem Lett 2: 337-341

  • DOI: 10.1021/ml1002579
  • Primary Citation of Related Structures:  
    3P9G, 3P9H

  • PubMed Abstract: 

    • Targeting protein-protein interactions is gaining greater recognition as an attractive approach to therapeutic development. An example of this may be found with the human cellular protein encoded by the tumor susceptibility gene 101 (Tsg101), where interaction with the p6 C-terminal domain of the nascent viral Gag protein is required for HIV-1 particle budding and release ...

    Targeting protein-protein interactions is gaining greater recognition as an attractive approach to therapeutic development. An example of this may be found with the human cellular protein encoded by the tumor susceptibility gene 101 (Tsg101), where interaction with the p6 C-terminal domain of the nascent viral Gag protein is required for HIV-1 particle budding and release. This association of Gag with Tsg101 is highly dependent on a "Pro-Thr-Ala-Pro" ("PTAP") peptide sequence within the p6 protein. Although p6-derived peptides offer potential starting points for developing Tsg101-binding inhibitors, the affinities of canonical peptides are outside the useful range (K(d) values greater than 50 μM). Reported herein are crystal structures of Tsg101 in complex with two structurally-modified PTAP-derived peptides. This data define new regions of ligand interaction not previously identified with canonical peptide sequences. This information could be highly useful in the design of Tsg101-binding antagonists.

    Organizational Affiliation: 

    Chemical Biology Laboratory, Molecular, Discovery Program, CCR, NCI-Frederick, Frederick, MD 21702.



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Tumor susceptibility gene 101 protein A145Homo sapiensMutation(s): 0 
Gene Names: TSG101
Find proteins for Q99816 (Homo sapiens)
Explore Q99816 
Go to UniProtKB:  Q99816
NIH Common Fund Data Resources
PHAROS:  Q99816
GTEx:  ENSG00000074319
Protein Feature View
Expand
  • Reference Sequence
  • Find similar proteins by:  Sequence   |   Structure
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetailsImage
Gag polyprotein B11N/AMutation(s): 0 
Find proteins for Q9YP46 (Human immunodeficiency virus 1)
Explore Q9YP46 
Go to UniProtKB:  Q9YP46
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
ZYK
Query on ZYK		BL-PEPTIDE LINKINGC14 H18 N2 O6PRO
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.80 Å
  • R-Value Free: 0.242 
  • R-Value Work: 0.197 
  • R-Value Observed: 0.197 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 33.556α = 90
b = 45.657β = 90
c = 88.521γ = 90
Software Package:
Software NamePurpose
StructureStudiodata collection
MOLREPphasing
CNSrefinement
HKL-2000data reduction
HKL-3000data scaling

Structure Validation

View Full Validation Report


View more in-depth experimental data

Entry History 

Deposition Data

  • Deposited Date: 2010-10-17 
  • Released Date: 2011-06-29 
    • Deposition Author(s): Hurley, J.H., Im, Y.J.

Revision History  (Full details and data files)

  • Version 1.0: 2011-06-29
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance